18F-DCFPyL PET-CT Scan and Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/27/2019 |
| Start Date: | July 22, 2018 |
| End Date: | June 30, 2020 |
| Contact: | Jafari Lida, M.D. |
| Email: | lida.jafari@va.gov |
| Phone: | 310 268 3583 |
A Novel 18F-DCFPyL PET-CT Scan for Diagnosis and Management of Prostate Cancer
Primary Objective:
The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for
initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP
bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the
percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease
at initial staging.
Secondary Objectives:
Frequency of the change in primary treatment plan after initial staging.
The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for
initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP
bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the
percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease
at initial staging.
Secondary Objectives:
Frequency of the change in primary treatment plan after initial staging.
This is a single arm Phase II clinical trial in Veterans with prostate cancer, no prior local
therapy, who are at risk of having metastatic disease (PSA greater than 10, or Gleason Score
greater than or equal to 4+3, or clinical stage greater than or equal to T2c). Veterans who
are planned to undergo or have recently undergone conventional, routine care initial staging
scans for prostate cancer (99mTc-MDP or NaF PET bone scan and diagnostic CT or MRI of pelvis)
will also receive a 18F-DCFPyL PET-CT scan. The primary endpoint is the percent of Veterans
with prostate cancer in which the 18F-DCFPyL PET-CT scan identifies evidence of M1 disease at
initial staging.
therapy, who are at risk of having metastatic disease (PSA greater than 10, or Gleason Score
greater than or equal to 4+3, or clinical stage greater than or equal to T2c). Veterans who
are planned to undergo or have recently undergone conventional, routine care initial staging
scans for prostate cancer (99mTc-MDP or NaF PET bone scan and diagnostic CT or MRI of pelvis)
will also receive a 18F-DCFPyL PET-CT scan. The primary endpoint is the percent of Veterans
with prostate cancer in which the 18F-DCFPyL PET-CT scan identifies evidence of M1 disease at
initial staging.
Inclusion Criteria:
1. Age ≥ 18 years and male.
2. Ability to understand the study and the willingness to sign a written informed consent
document.
3. Histologically confirmed adenocarcinoma of the prostate.
4. PSA greater than 10, or Gleason ≥4+3, or clinical stage greater than or equal toT2c.
5. Plan to undergo (or have already undergone) routine care initial systemic staging with
conventional imaging for prostate cancer.
6. Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.
7. No prior local therapy for prostate cancer (i.e., prostatectomy, radiotherapy, etc.).
8. Willing to comply with the procedural requirements of this protocol.
Exclusion Criteria:
1. Serious or uncontrolled co-existent non-malignant disease, including active and
uncontrolled infection.
2. The subject has a condition or situation that, in the investigator's opinion, may put
the subject at significant risk, may confound the study results, or may interfere
significantly with subject's participation in the study.
3. Primary small cell carcinoma of the prostate.
4. Participation in this study significantly delay the scheduled standard of care
therapy.
5. Weighs greater than 350 lbs., or unable to fit within the imaging gantry.
6. The subject undergone prior local therapy for prostate cancer (i.e. prostatectomy,
radiotherapy, etc.).
7. Currently receiving androgen deprivation therapy (ADT) or anti-androgen? Previous use
of ADT is allowed IF the subject has been off ADT or anti-androgen for 3 months or
more.
We found this trial at
1
site
Click here to add this to my saved trials
